Neoprobe Interviewed by WallSt.net; CFO Provides Business Update.
The Neoprobe Corporation interview is available at http://www.WallSt.net. If you are not already a wallst.net subscriber, you may sign up for free by clicking on the "Sign me up - FREE!" button at the top of the page. After establishing your user ID and password, click on the "Submit" button at the top of the page. This will register you and send you back to the WallSt.net home page. You may access the interview by clicking on the "Interview" button on the toolbar near the top of the page and entering the trading symbol "NEOP" in the Search Archive dialog box mid-way down the page.
Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neo2000(R) line of gamma detection systems that are widely used by cancer surgeons and is commercializing the Quantix(R) line of blood flow measurement products developed by its subsidiary, Cardiosonix Ltd. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek(TM) and RIGScan(R) CR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 31, 2006|
|Previous Article:||Fitch Ratings Affirms CMBS/Realty One Securitization Trust 2002-1.|
|Next Article:||Fitch Affirms Banco Santander Serfin's Ratings.|